CION Ameerpet
Genetics · Reviewed by CION Oncologists · NABH Accredited
Preventing Cancer With Lynch Syndrome
Lynch syndrome is one of the few situations in cancer medicine where prevention genuinely works, and works measurably. Four things carry real evidence: regular colonoscopy, aspirin, risk-reducing surgery, and prompt assessment of symptoms between appointments. They are not equally strong, they do not all apply to everyone, and the evidence for each covers particular cancers rather than all of them — a distinction this page is careful about. What follows sets out what each measure actually achieves, so you can have a specific conversation with your genetics team rather than a general one.
- Colonoscopy prevents, not just detects — polyps are removed before they progress
- Aspirin has randomised trial evidence — strongest for bowel cancer specifically
- Surgery addresses the gynaecological risk — once childbearing is complete
- Symptoms still trump schedules — surveillance sees only what is there that day
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What Actually Reduces Risk
Graded by strength of evidence, and specific about which cancers each measure addresses.
| Measure | What the evidence supports |
|---|---|
| Regular colonoscopy | The strongest measure available. Because bowel cancers arise from polyps that can be removed during the procedure, colonoscopy prevents cancers rather than merely finding them early, and is associated with reduced bowel cancer deaths in Lynch syndrome. Intervals are set by your gene and history. See Lynch surveillance. |
| Aspirin | Randomised trial evidence supports a reduction in bowel cancer incidence in carriers taking it regularly over years, with benefit emerging after several years. Recommended for many carriers. Dose, duration and suitability are individualised and account for bleeding risk — a prescription, not a supermarket decision. |
| Risk-reducing gynaecological surgery | Removing the uterus, tubes and ovaries addresses the endometrial and ovarian risk far more effectively than surveillance can. Discussed once childbearing is complete, and a genuine decision rather than a recommendation. See risk-reducing surgery. |
| Prompt assessment of symptoms | Not a test, and arguably the highest-value habit on this list. Surveillance detects what is present on the day; anything arising between appointments needs assessment when it arises. For the uterus this matters most, since bleeding is the signal. See bleeding after menopause. |
| Testing your relatives | Prevention for other people, which is easy to overlook. Each first-degree relative has a one in two chance of carrying the variant, and those who do gain access to surveillance that demonstrably reduces deaths. See testing your family. |
| Treating Helicobacter pylori | Testing for and eradicating this common stomach infection is generally recommended, since it contributes to stomach cancer risk. Straightforward, one-off, and worth doing. |
| Weight, activity and not smoking | Contribute as they do for everyone, and there is evidence that weight and smoking influence risk in carriers too. Not a substitute for the measures above, and worth doing alongside them. See diet and exercise. |
Be precise about which cancer each measure addresses. Colonoscopy and aspirin are about the bowel. Surgery is about the uterus and ovaries. Symptom vigilance covers everything. A prevention plan that is strong on one organ and silent on another is a common and avoidable gap — ask for it in writing, covering all of them.
Did You Know? The aspirin finding is one of the more striking results in cancer prevention. A randomised controlled trial in people with Lynch syndrome found that regular aspirin over a period of years reduced the incidence of colorectal cancer, with the benefit becoming apparent some years after starting and persisting long afterwards. That is unusual: very few interventions have randomised evidence for preventing cancer in a defined high-risk group. Two caveats matter. The evidence is strongest for bowel cancer, and it should not be assumed to extend to endometrial cancer, where it is not established. And aspirin carries a bleeding risk, so who takes it, at what dose and for how long is a clinical decision rather than a self-directed one. Sources: CAPP2 randomised controlled trial of aspirin in Lynch syndrome; NICE guidance on aspirin for preventing colorectal cancer in Lynch syndrome; NCCN Clinical Practice Guidelines in Oncology — Genetic/Familial High-Risk Assessment: Colorectal, Endometrial and Gastric.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Aspirin — What Is and Is Not Established
Worth being precise about, because this is where confident overstatement is commonest.
- The evidence is for bowel cancer. A randomised controlled trial in Lynch syndrome carriers found reduced colorectal cancer incidence with regular aspirin over a period of years. That is the established finding.
- It should not be assumed to prevent endometrial cancer. That is not established, and presenting it as though it were would be misleading. For the uterus, the measures that count are prompt assessment of bleeding and, where chosen, risk-reducing surgery.
- Benefit takes years to appear. This is not a short-term intervention. The protective effect emerged some years after starting and persisted afterwards, which means the decision is about a sustained commitment.
- Bleeding risk is real and must be weighed. Aspirin increases the risk of gastrointestinal and other bleeding. Whether it is right for you depends on your own history, other medicines and other conditions.
- Dose and duration are individualised. They are decided by your genetics or gastroenterology team rather than being uniform, which is why no dose appears on this page. Do not start aspirin on the basis of a web page — including this one.
Want Your Prevention Plan Reviewed?
Bowel, gynaecological and general measures set out together, in writing, for your specific gene.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Do Not Start Aspirin From a Web Page
The evidence is real and so is the bleeding risk. Dose and suitability are a clinical decision.
Where Prevention Plans Commonly Fall Down
Not clinical failures so much as organisational ones, and all five are avoidable.
The plan covers the bowel and forgets the uterus
Lynch syndrome is widely thought of as a bowel condition, and gastroenterology often leads the care. The gynaecological side then gets less attention than it warrants — particularly for MSH6 carriers, whose endometrial risk is substantial while their bowel risk is lower. Ask explicitly what your plan says about the uterus and ovaries.
Nobody owns the recall
Surveillance runs for decades across several departments, and responsibility for calling you back is easy to lose between them — after a move, a change of hospital, or a doctor retiring. Ask whose list you are on for each element and keep your own diary as a backstop.
Aspirin is started and never reviewed
It is a long-term medicine with a bleeding risk that changes as you age and as other medicines are added. It belongs in a periodic review rather than continuing indefinitely by default. Ask when it will next be reconsidered.
Family testing stalls
The highest-value action available to you, and the one most often postponed. Each first-degree relative has a one in two chance of carrying the variant, and those who do gain access to surveillance that reduces deaths. A genetics service will help with how to raise it. See testing your family.
Symptoms get saved up for the next appointment
The most consequential of the five. Surveillance detects what is present on the day it is done. Anything new between appointments — and for the uterus, any abnormal bleeding at all — needs assessment when it arises, not at the next scheduled visit.
Want Your Whole Prevention Plan Checked?
Bring your genetic report. Bowel, gynaecological and general measures reviewed together. The opinion is free.
Why This Is a More Hopeful Position Than It Sounds
A genetic diagnosis lands badly. It is worth setting out what it actually buys you.
- You know, and most people do not. The great majority of people carrying a Lynch variant are unaware of it and receive no surveillance at all. Knowing is what makes prevention possible.
- Colonoscopy is genuinely preventive. Not early detection but prevention — polyps removed before they can become cancers. Few interventions in medicine can claim that.
- Carrying a variant does not mean you will develop cancer. Even for higher-risk genes, a meaningful proportion of carriers never do. Lifetime figures describe groups across decades.
- Lynch-related cancers respond distinctively well. Mismatch repair deficient tumours have features that make particular classes of treatment effective, which is part of why outcomes are often better than the risk figures suggest. See Lynch-related endometrial cancer.
- The anxiety is treatable too. Many carriers find the period around each appointment difficult, and that is common rather than a failure of coping. It is worth raising. See coping with a diagnosis.
Why Prevention Needs Coordinating
Three specialties, several decades, and one plan that has to survive all of it.
Lynch counselling built in
One place for the whole pathway
Follow-up you can actually keep
Tumour board for every diagnosis
Named MCh surgical oncologists
Costs explained before you commit
Take The Next Step
Ask What Your Plan Says About the Uterus
Lynch care is often bowel-led. The gynaecological half is the part most likely to be thin.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Preventing Lynch Cancers — Frequently Asked Questions
Does aspirin really prevent cancer in Lynch syndrome?
For bowel cancer, yes — this is supported by randomised controlled trial evidence in Lynch syndrome carriers, which found that regular aspirin taken over a period of years reduced colorectal cancer incidence, with the benefit emerging some years after starting and persisting afterwards. That is an unusually strong result for a cancer prevention measure. Two things must be said alongside it. The evidence is for bowel cancer and should not be assumed to extend to endometrial cancer, where it is not established. And aspirin carries a real bleeding risk, so whether it is right for you, at what dose and for how long, is a decision for your genetics or gastroenterology team rather than one to make from a web page.
What dose of aspirin should I take?
This page deliberately does not give a dose, and you should not start aspirin on the basis of any website. Dose and duration are individualised, and the decision weighs your bleeding risk, your other medicines, your other conditions and your specific gene. It is a prescribing decision made by the team that knows your history. If aspirin has been discussed with you and you are unclear about the dose or how long to continue, that is a question worth putting directly to your genetics service — and worth asking when the decision will next be reviewed, since it is a long-term medicine whose risk profile changes with age.
What prevents endometrial cancer specifically in Lynch syndrome?
Two things, and it is worth being clear that aspirin is not established as one of them. The first is prompt assessment of any abnormal bleeding — this is the measure that matters most, because endometrial cancer signals through bleeding and responding to it promptly is what catches disease while it is confined to the uterus. Do not save a symptom for the next scheduled appointment. The second is risk-reducing hysterectomy with removal of the tubes and ovaries, discussed once childbearing is complete, which removes the risk rather than monitoring it. Gynaecological surveillance may be offered, though its evidence base is weaker than that for colonoscopy.
Is surveillance enough on its own, or do I need surgery?
It depends on the organ. For the bowel, surveillance is genuinely powerful — colonoscopy removes polyps before they progress, so it prevents cancers rather than merely detecting them, and surgery is not part of routine prevention. For the uterus and ovaries the position is weaker: no gynaecological surveillance test has been shown to reduce endometrial cancer deaths the way colonoscopy reduces bowel cancer deaths, and ovarian cancer has no effective screening at all. That gap is the reason risk-reducing surgery is discussed. It is a genuine decision rather than a recommendation, and both accepting and declining it are reasonable depending on your gene, age and circumstances.
What is the single most useful thing I can do?
Two candidates, and they are both unglamorous. The first is to have any new symptom assessed when it arises rather than saving it for the next surveillance appointment — surveillance detects only what is present on the day it is done, and for the uterus in particular, any abnormal bleeding should be assessed promptly. The second is to get your relatives tested. Each first-degree relative has a one in two chance of carrying the same variant, and those who do gain access to surveillance that demonstrably reduces bowel cancer deaths. It is the highest-value action available to you and the one most commonly postponed.
Medical disclaimer: This page provides general information about cancer prevention in Lynch syndrome, reviewed by a CION oncologist. It is not a substitute for genetic counselling or individual medical advice. Aspirin should not be started without medical advice: dose, duration and suitability are individualised and must be weighed against bleeding risk. Surveillance schedules and preventive measures are set by a clinical genetics service according to the specific gene involved. Any abnormal bleeding should be assessed promptly rather than deferred to the next scheduled appointment.